Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting.
Resource Type
Editorial & Opinion
Authors
Singh A; Divisions of Hematology Rochester, Mayo Clinic, Rochester, Minnesota, USA.; Al-Kali A; Divisions of Hematology Rochester, Mayo Clinic, Rochester, Minnesota, USA.; Foran JM; Jacksonville, Mayo Clinic, Rochester, Minnesota, USA.; Elliott MA; Divisions of Hematology Rochester, Mayo Clinic, Rochester, Minnesota, USA.; Begna K; Divisions of Hematology Rochester, Mayo Clinic, Rochester, Minnesota, USA.; Badar T; Divisions of Hematology Rochester, Mayo Clinic, Rochester, Minnesota, USA.; Khera N; Scottsdale, Mayo Clinic, Rochester, Minnesota, USA.; Fleti F; Divisions of Hematology Rochester, Mayo Clinic, Rochester, Minnesota, USA.; Abdelmagid M; Divisions of Hematology Rochester, Mayo Clinic, Rochester, Minnesota, USA.; Reichard KK; Division of Hematopathology, Rochester, Mayo Clinic, Rochester, Minnesota, USA.; Ketterling RP; Division of Hematopathology, Rochester, Mayo Clinic, Rochester, Minnesota, USA.; Pardanani A; Divisions of Hematology Rochester, Mayo Clinic, Rochester, Minnesota, USA.; Gangat N; Divisions of Hematology Rochester, Mayo Clinic, Rochester, Minnesota, USA.; Tefferi A; Divisions of Hematology Rochester, Mayo Clinic, Rochester, Minnesota, USA.
Source
Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE